トラマールＯＤ錠２５ｍｇ
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00193 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 100 |
| 日本商品名（例） | トラマドール塩酸塩ＯＤ錠２５ｍｇ「ＫＯ」, トラマドール塩酸塩ＯＤ錠５０ｍｇ「ＫＯ」, トラマールＯＤ錠２５ｍｇ |
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | osteoarthritis susceptibility | 99% | DL |
| 2 | osteoarthritis | 99% | DL |
| 3 | arthropathy | 99% | DL |
| 4 | acromesomelic dysplasia, Hunter-Thompson type | 99% | DL |
| 5 | brachyolmia-amelogenesis imperfecta syndrome | 99% | DL |
| 6 | myosclerosis | 99% | DL |
| 7 | brachyolmia | 99% | DL |
| 8 | pseudoachondroplasia | 99% | DL |
| 9 | spondyloarthropathy, susceptibility to | 99% | DL |
| 10 | juvenile idiopathic arthritis | 99% | DL |
| 11 | juvenile arthritis due to defect in LACC1 | 99% | DL |
| 12 | rheumatoid nodulosis | 99% | DL |
| 13 | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis | 99% | DL |
| 14 | juvenile chronic polyarthritis | 99% | DL |
| 15 | ankylosing spondylitis | 99% | DL |
| 16 | WHIM syndrome | 99% | DL |
| 17 | rheumatoid arthritis | 99% | DL |
| 18 | myofascial pain syndrome | 99% | DL |
| 19 | brachydactyly-syndactyly syndrome | 99% | DL |
| 20 | hypermobility of coccyx | 99% | DL |
| 21 | rheumatoid vasculitis | 99% | DL |
| 22 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 99% | DL |
| 23 | inflammatory spondylopathy | 99% | DL |
| 24 | Kummell disease | 99% | DL |
| 25 | polyarticular juvenile rheumatoid arthritis | 99% | DL |
| 26 | vertebral disease | 99% | DL |
| 27 | obsolete vascular headache | 99% | DL |
| 28 | Behr syndrome | 99% | DL |
| 29 | spondyloarthropathy | 99% | DL |
| 30 | avascular necrosis of femoral head, primary | 99% | DL |
| 31 | combined immunodeficiency due to moesin deficiency | 99% | DL |
| 32 | atherosclerosis susceptibility | 98% | DL |
| 33 | ankylosis (disease) | 98% | DL |
| 34 | 14q32 duplication syndrome | 98% | DL |
| 35 | bursitis | 98% | DL |
| 36 | otitis media, susceptibility to | 98% | DL |
| 37 | bulimia nervosa, susceptibility to | 98% | DL |
| 38 | Czech dysplasia, metatarsal type | 98% | DL |
| 39 | orofacial cleft 6, susceptibility to | 98% | DL |
| 40 | Stickler syndrome, type I, nonsyndromic ocular | 98% | DL |
| 41 | spondyloepimetaphyseal dysplasia, Handigodu type | 98% | DL |
| 42 | vertebral joint disease | 98% | DL |
| 43 | platyspondylic dysplasia, Torrance type | 98% | DL |
| 44 | aortic aneurysm, familial thoracic 11, susceptibility to | 98% | DL |
| 45 | atrioventricular septal defect, susceptibility to, 2 | 98% | DL |
| 46 | transient arthropathy | 98% | DL |
| 47 | spondylometaphyseal dysplasia, Schmidt type | 98% | DL |
| 48 | systemic lupus erythematosus, susceptibility to | 98% | DL |
| 49 | scoliosis, isolated, susceptibility to | 98% | DL |
| 50 | dysplastic nevus syndrome | 98% | DL |
（上位50件を表示。全100件の予測があります）
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。